Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Saruparib by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Saruparib by AstraZeneca for Metastatic Prostate Cancer: Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase III for Metastatic Prostate Cancer. According to GlobalData, Phase...
Saruparib by AstraZeneca for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...
Saruparib by AstraZeneca for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Saruparib is under clinical development by AstraZeneca and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...